Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

RCT (n=20) found that therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation (successful liberation HR 4.0; 95% CI 1.035–15.053 and more ventilator-free days: 15 vs. 0 days) in severe COVID–19 vs. standard anticoagulant thromboprophylaxis.

Source:

Thrombosis Reasearch